Nexeon MedSystems (OTCMKTS:NXNN – Get Rating) and Hyperfine (NASDAQ:HYPR – Get Rating) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.
Risk and Volatility
Nexeon MedSystems has a beta of 7.3, suggesting that its share price is 630% more volatile than the S&P 500. Comparatively, Hyperfine has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
This table compares Nexeon MedSystems and Hyperfine’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
Earnings and Valuation
This table compares Nexeon MedSystems and Hyperfine’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Hyperfine||$1.50 million||37.59||-$64.85 million||($3.59)||-0.22|
Nexeon MedSystems has higher earnings, but lower revenue than Hyperfine.
This is a summary of current ratings and target prices for Nexeon MedSystems and Hyperfine, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Hyperfine has a consensus price target of $4.30, suggesting a potential upside of 438.31%. Given Hyperfine’s higher possible upside, analysts plainly believe Hyperfine is more favorable than Nexeon MedSystems.
Nexeon MedSystems beats Hyperfine on 5 of the 9 factors compared between the two stocks.
About Nexeon MedSystems
Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.
Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.
Receive News & Ratings for Nexeon MedSystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexeon MedSystems and related companies with MarketBeat.com's FREE daily email newsletter.